What are the challenges of targeting SIRPα in Cancer Therapy?
While targeting the SIRPα-CD47 pathway is a promising strategy, several challenges remain. One major issue is the potential for off-target effects, as CD47 is also expressed on normal cells, which could lead to autoimmune reactions or anemia. Additionally, the redundancy and complexity of the immune system mean that compensatory mechanisms may reduce the efficacy of SIRPα-CD47 blockade.
